Levotonal (Calcium Levofolinate)

Calcium Levofolinate provides a reduced form of folic acid that enters cells via the reduced folate carrier. It bypasses the dihydrofolate reductase block imposed by methotrexate, allowing conversion to tetrahydrofolate derivatives that supply one‑carbon units for thymidylate and purine synthesis, thereby restoring DNA replication.

The dose of Levotonal is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent chemotherapy regimen. Healthcare professionals set the appropriate amount and schedule for each patient.

The pregnancy safety category for Levotonal is not established. It should only be used during pregnancy or lactation when the potential benefits justify any possible risk to the fetus or infant, and after careful evaluation by the treating physician.

To order Levotonal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

The primary alternative to Levotonal is leucovorin (folinic acid). Both provide reduced folate to rescue cells from methotrexate toxicity, but calcium levofolinate is a calcium‑salt formulation that may offer improved stability for injectable use. Clinical choice depends on formulation preferences, dosing convenience and institutional protocols.

Levotonal must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to local regulations.

Levotonal is supplied as a sterile solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, typically shortly after high‑dose methotrexate infusion, following the dosing schedule prescribed by the treating physician.

Serious adverse events include anaphylaxis, severe hypotension, acute renal failure, marked hepatic dysfunction, neutropenia and thrombocytopenia. Patients should be monitored closely for signs of allergic reaction, sudden drop in blood pressure, impaired kidney or liver function, and abnormal blood counts.

Levotonal is contraindicated in patients with known hypersensitivity to calcium levofolinate or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnant women unless the therapeutic benefit outweighs potential risks.